Relationship Between Depression Severity Entry Criteria and Antidepressant Clinical Trial Outcomes

Biological Psychiatry

Volumn 62, Issue 1, 2007, Pages 65-71

  Khan, Arif ^a,b   Schwartz, Kelly ^a   Kolts, Russell L ^c   Ridgway, Derry ^d   Lineberry, Charles ^d  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c EASTERN WASHINGTON UNIVERSITY   (United States)

^d Lineberry Associates   (United States)

Author keywords

Antidepressant clinical trial outcome; antidepressants; depression; Hamilton Depression Rating Scale; placebo; randomized clinical trial

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; HUMANS; PATIENT SELECTION; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34250174824     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.08.036     Document Type: Article

References (24)

1. Bollini P., Pampallona S., Tibaldi G., Kupelnick B., and Munizza C. Effectiveness of antidepressants. Meta-analysis of dose effect relationships in randomized clinical trials. Br J Psychiatry 174 (1999) 297-303
2. Brown W.A. Predictors of placebo response in depression. Psychopharmacol Bull 24 (1988) 14-17
3. Dworkin R.H., Katz J., and Gitlin M.J. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology 65 suppl 4 (2005) S7-S19
4. Elkin E., Shea T., Watkins J.T., Imber S.D., Sotsky S.M., Collins J.F., et al. General effectiveness of treatments. Arch Gen Psychiatry 46 (1989) 971-982
5. Gram L.F. Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clin Neuropharmacol 3 (1990) S35-S44
6. Greist J.H., Mundt J.C., and Kobak K. Factors contributing to failed trials of new agents: Can technology prevent some problems?. J Clin Psychiatry 63 suppl 2 (2002) 8-13
7. Gunnell D., Saperia J., and Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomized controlled trials submitted to the MHRA's safety review. BMJ 330 (2005) 385-389
8. Joffe R., Sokolov S., and Streiner D. Antidepressant treatment of depression: A meta-analysis. Can J Psychiatry 41 (1996) 613-616
9. Joyce P.R., and Paykel E.S. Predictors of drug response in depression. Arch Gen Psychiatry 46 (1989) 89-99
10. Kasper S., Fuger J., and Moller H.J. Comparative efficacy of antidepressants. Drugs 42 (1992) 11-23
11. Khan A., Brodhead A.E., Kolts R.L., and Brown W.A. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 39 (2005) 145-150
12. Khan A., Khan S., and Brown W.A. Are placebo controls necessary to test new antidepressants and anxiolytics?. Int J Neuropsychopharmacol 5 (2002) 193-197
13. Khan A., Khan S.R., Walens G., Kolts R., and Giller E.L. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration Summary Basis of Approval Reports. Neuropsychopharmacology 28 (2003) 552-557
14. Khan A., Kolts R.L., Thase M.E., Krishnan K.R.R., and Brown W. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 161 (2004) 2045-2049
15. Khan A., Leventhal R.M., Khan S.R., and Brown W.A. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration Database. J Clin Psychopharmacol 22 (2002) 40-45
16. Khan A., and Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol 6 (2005) 221-226
17. Leon A.C. Are two antidepressant mechanisms better than one?. Issues in clinical trial design and analysis. J Clin Psychiatry 65 suppl 4 (2004) 31-36
18. Morris J.B., and Beck A.T. The efficacy of antidepressant drugs. Arch Gen Psychiatry 31 (1974) 33-41
19. Quitkin F.M., Rabkin J.F., Markowitz J.M., Stewart J.W., McGrath P.G., and Harrison W. Use of pattern analysis to identify true drug response: A replication. Arch Gen Psychiatry 44 (1987) 259-264
20. Schatzberg A.F. Dosing strategies for antidepressant agents. J Clin Psychiatry 52 suppl (1991) 14-20
21. Thase M.E. Studying new antidepressants: If there were a light at the end of the tunnel, could we see it?. J Clin Psychiatry 63 suppl 2 (2002) 24-28
22. Walsh B.T., Seidman S.N., Sysko R., and Gould M. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 287 (2002) 1840-1847
23. Wilcox C.S., Cohn J.B., Linden R.D., Heiser J.F., Lucas P.B., Morgan D.L., et al. Predictors of placebo response: A retrospective analysis. Psychopharmacol Bull 28 (1992) 157-162
24. Yang H., Cusin C., and Fava M. Is there a placebo problem in antidepressant trials?. Curr Top Med Chem 5 (2005) 1077-1086